MHRA grants marketing authorisation for Novartis’ Pluvicto

12th August 2022 Uncategorised 0

Radioligand therapy involves patients with advanced prostate cancer in Great Britain

More: MHRA grants marketing authorisation for Novartis’ Pluvicto
Source: News